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Background: Pharmacological neuroenhancement (PN) is defined as the use of illicit or
prescription drugs by healthy individuals for cognitive-enhancing purposes. The present
study aimed (i) to investigate whether including caffeine tablets in the definition of PN
within a questionnaire increases the PN prevalence estimate (framing effect), (ii) to
investigate whether the health-related risk attitude is increased in students who use
PN.
Materials and methods: Two versions of a paper-and-pencil questionnaire (first
version included caffeine tablets in the definition of PN, the second excluded caffeine
tablets) were distributed among university students at the University of Graz, Austria.
The unrelated question model (UQM) was used to estimate the 12-month PN prevalence
and the German version of the 30-item Domain-Specific Risk-Taking (DOSPERT) scale
to assess the health-related risk attitude. Moreover, large-sample z-tests (α = 0.05) were
performed for comparing the PN prevalence estimates of two groups.
Results: Two thousand four hundred and eighty-nine questionnaires were distributed
and 2,284 (91.8%) questionnaires were included in analysis. The overall PN prevalence
estimate for all students was 11.9%. One-tailed large-sample z-tests revealed that the
PN estimate for students with higher health-related risk attitude was significantly higher
compared to students with lower health-related risk attitude (15.6 vs. 8.5%; z = 2.65,
p = 0.004). Furthermore, when caffeine tablets were included into the example of PN,
the prevalence estimate of PN was significantly higher compared to the version without
caffeine tablets (14.9 vs. 9.0%; z = 2.20, p = 0.014).
Discussion: This study revealed that the PN prevalence estimate increases when
caffeine tablets are included in the definition of PN. Therefore, future studies investigating
the prevalence of, and predictors for, PN should be performed and interpreted with
respect to potential framing effects. This study further revealed that the PN prevalence
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estimate is increased in students with a higher health-related risk attitude compared
to students with a lower one. Therefore, future education and prevention programs
addressing PN in the collective of students should not only inform about potential
side effects of its use but also address the limited effects on cognition and potential
alternatives of PN.
Keywords: message frame, cognitive bias, cognitive enhancing drugs, risk behavior, substance abuse detection,
statistical distributions, epidemiologic methods, randomized response technique
INTRODUCTION
The term “pharmacological neuroenhancement (PN)” – also
called “pharmacological cognitive enhancement” – is generally
defined as the use of illicit (e.g., illicit stimulants, cocaine, ecstasy)
or prescription drugs (e.g., stimulants such as methylphenidate
and amphetamines, modafinil as well as antidementives and
antidepressants) by healthy individuals for cognitive-enhancing
purposes such as improving vigilance, attention, concentration,
or mood (Franke and Lieb, 2010; Dietz et al., 2013b;
Sattler, 2016). In the last decade, a considerable number
of epidemiological studies using different survey methods
investigated the prevalence of PN in various populations. For
example, based on a survey by a large German health insurance
company, a lifetime prevalence of 5% for PN was reported
for the general working population in Germany (DAK, 2009),
and lifetime prevalences of about 20% for scientists (Maher,
2008), surgeons (Franke et al., 2013), and economists (Dietz
et al., 2016b). In addition, a systematic review by Wilens et al.
(2008) estimated a lifetime prevalence for the use of stimulants
including prescription and illicit drugs of 5–9% in graduate
and high school students, and 5–35% among college students
in the United States (Wilens et al., 2008). Similar results were
obtained for student collectives in Western Europe. For example,
lifetime prevalences for the use of prescription drugs of 8%
and 9% were reported for pupils in Germany (Wolff and
Brand, 2013) and Switzerland (Liakoni et al., 2015), respectively.
Moreover, for university students the lifetime prevalence was
about 5% for the use of prescription drugs for cognitive-
enhancing purposes among German students (Sattler and Wiegel,
2013), 7.6% among Swiss students (Maier et al., 2013), around
2% among Dutch students (Schelle et al., 2015), 16% for the
use of drugs among Italian students (Castaldi et al., 2012), and
about 4% for the use of methylphenidate, 6% for modafinil,
and 2% for Adderall for cognitive-enhancing purposes among
students in Ireland/United Kingdom (Singh et al., 2014). Using
an indirect survey technique, Dietz et al. (2013a) estimated a 12-
month prevalence of 20% for PN for German university students
including prescription drugs, illicit drugs, and caffeine tablets.
The heterogeneity of the prevalence estimates across studies
can be attributed to various factors. For example, some studies
employed direct and others indirect questioning methods
(Lensvelt-Mulders et al., 2005b; Simon et al., 2006; Franke et al.,
2013) when assessing such sensitive issues (Sieber and Stanley,
1988; Lee and Renzetti, 1990). In addition, some studies assessed
the prevalence for a single substance (e.g., methylphenidate only)
while other studies for a whole group of substances. Finally,
studies also differed with respect to the definition and description
of PN (Sattler, 2016; Schleim and Quednow, 2017). The latter
issue can produce framing effects that biases people’s responses
(Rothman et al., 1993; Stocké, 2002; Plous, 2007). In order to
omit such bias effects like social desirability, Dietz et al. (2013a,b)
conducted two surveys to estimate PN prevalence in university
students and triathletes using an indirect survey technique. In
these latter studies, the terms “illicit and prescription drugs” were
explicitly defined in the survey questionnaire as “. . .substances
which can only be prescribed by a doctor, are available in a
pharmacy, or can be bought on the black market (e.g., caffeine
tablets, stimulants, cocaine, methylphenidate, modafinil, beta-
blockers) and are used to enhance your cognitive performance.”
Although caffeine tablets are not illicit and hence a prescription
is not needed to receive them, the authors included caffeine
tablets in their example of PN because in Germany (in contrast
to the United States), caffeine tablets can only be bought
in pharmacies and not in supermarkets or drug-stores. In
addition, the consumption of caffeine tablets differs markedly
from the consumption of a cup of coffee, because coffee may
also be consumed for appetite whereas the only reason for
consuming caffeine tablets would be to reduce fatigue (Franke
et al., 2011b, 2015). Other authors have argued that prevalence
estimates for PN of 20% in university students and 15.1% in
triathletes are particularly a consequence of this inclusion of
caffeine tablets in the definition of PN (Maier et al., 2013;
Liakoni et al., 2015; Maier and Schaub, 2015; Schleim and
Quednow, 2017), even though other studies revealed quite
comparable results without including caffeine tablets (Maher,
2008; Franke et al., 2013; Dietz et al., 2016b). Nonetheless,
although postulated by scientists to be needed (Schleim and
Quednow, 2017), no systematic research has been conducted
whether the inclusion of caffeine tablets in the definition of PN
increases PN prevalence estimates. Given that 11% of students
(Franke et al., 2011b) and 13% of surgeons (Franke et al., 2015)
reported to have used caffeine tablets for cognitive-enhancing
purposes once in their life, we hypothesized that including
caffeine tablets in the definition of PN would increase PN
prevalence estimates compared to excluding caffeine tablets in the
definition.
Furthermore, PN consumption is, depending on dosage,
associated with diverse adverse acute and chronic effects on
physical and mental health, has been assumed to lead to
addiction and produces a gateway to other drugs (Kumar,
2008; Dietz et al., 2013b; Wolff and Brand, 2013; LaBotz and
Griesemer, 2016). For example, stimulant use is associated with
the risk of cardiovascular events, hypertonia, tachycardia, and
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even sudden cardiac death (Kumar, 2008). In addition, long-
term use of methylphenidate has been associated with neuronal
changes comparable to those of cocaine use (Steiner and van
Waes, 2013; Noble et al., 2015). A qualitative study among
19 university students in Australia revealed that students were
aware of potential side effects of PN (Partridge et al., 2013).
Fortunately, knowing potential side effects of PN reduces the
willingness to consume PN (Sattler et al., 2014). Consequently,
it has been assumed that the prospect of expected side effects
from drug use acts as a protective factor against PN (Sattler
and Wiegel, 2013). However, knowing about health risks does
not necessarily prevent everybody from using PN, and several
studies indicated that increased risk-taking behavior is associated
with drug use (Khan et al., 2012; Noble et al., 2015; Nicholls
et al., 2017). Furthermore, a study performed by Maier et al.
(2015) comparing personality traits/attitudes of users of PN
and non-users indicated that risk-taking-related personality
traits/attitudes such as novelty seeking, self-reported impulsivity
as well as antisocial personality were increased in users of
PN compared to controls (Maier et al., 2015). Therefore, we
hypothesized that people who consume PN have an increased
health-related risk attitude compared to people who do not
consume PN.
The present study aimed to address the following: (i) to
investigate whether including caffeine tablets in the definition
of PN within a questionnaire increases the PN prevalence
estimate, (ii) to investigate whether the health-related risk
attitude is increased in students who use PN, by providing first
evidence on the prevalence of PN in Austrian university students.
Investigating these knowledge gaps is of public health concern
in order to develop more individually tailored education and
prevention concepts.
MATERIALS AND METHODS
Survey Procedure
A paper-and-pencil survey was conducted among university
students at the University of Graz, Austria. The study
administration online platform of the university was used
to identify all major classes from different disciplines during
the summer term of 2017. Two weeks before the survey
was distributed, all teachers/lecturers of the identified classes
were informed about the study and the procedure by email.
The email also requested consent to distribute the survey
in their classes. When consent was obtained, a trained team
of assistants visited the classes one-time and distributed the
questionnaires (two versions, one per participant; for more
details see the section on “questionnaire” below). In a short
verbal introduction, the assistants stressed the anonymity of
the study and told the students to fill in the questionnaire
immediately and to drop it into black boxes that were set
up in the lecture hall. They further emphasized that all
questionnaires had to be returned regardless if they were
completed or not in order enable an accurate calculation of the
response rate. The whole procedure lasted 10–15 min. Ethical
approval to conduct this study was obtained by the Ethics
Committee of the University of Graz, Austria (GZ. 39/40/63 ex
2016/17).
Questionnaire
The anonymous paper-and-pencil questionnaire was two pages
long and, after a short introduction explaining the content of the
study and that participation would be anonymous and voluntary,
was comprised of three parts. The first part addressed the 12-
month prevalence of PN using the unrelated question model
(UQM; Greenberg et al., 1969), a randomized response technique
developed specifically to obtain more valid prevalence estimates
when sensitive topics are studied by guaranteeing anonymity
(Warner, 1965, 1971). The methodological background of the
UQM as used for the present study has been explicitly described
in several previous articles (Dietz et al., 2013a,b, 2016a; Franke
et al., 2013, 2017; Schröter et al., 2016) and will therefore not be
repeated in detail. In short, participants had to consider a certain
birthday (of their mother). If this birthday was in the first third of
the month (1st to 10th day), they had to answer a neutral question
and if not, they had to answer the sensitive question regarding
the prevalence of PN. Thus, the probability for receiving the
neutral question was 120/365.25 and the probability for receiving
the sensitive question was 245.25/365.25. The neutral question
asked whether the birthday they considered is in the first half
of the year (before 1st of July). Therefore, the probability for
answering the neutral question with ‘yes’ (denoted as pin) was
181.25/365.25. The proportion of ‘yes’ responses with respect to
the sensitive question (i.e., the prevalence estimate pˆis) can then
be derived from the proportion of total ‘yes’ responses in the
sample (denoted as a). A specific arithmetic example is given in
the publication of Franke et al. (2013).
The translated wording of the sensitive question regarding
PN was “for the purpose of enhancing your cognitive
performance during studying, have you used substances which
are only available in a pharmacy, can be prescribed by
a doctor or can be bought on the black marked during
the last 12 month (examples).” We used two different
questionnaire versions containing different versions of the
example for substances. The first version included caffeine
tablets in the example “(e.g., caffeine tablets, stimulants, cocaine,
methylphenidate, beta-blockers, modafinil)” and the second did
not “(e.g., stimulants, cocaine, methylphenidate, beta-blockers,
modafinil).” This procedure enabled us to calculate two different
PN prevalence estimates, one for including caffeine tablets and
one for excluding caffeine tablets. The order for distributing
the two questionnaire versions was determined by simple
randomization (Altman and Bland, 1999; Schulz and Grimes,
2007) using Windows Excel (questionnaires with an uneven
number included caffeine tablets, questionnaires with an even
numbers did not). Within the second part of the questionnaire, we
assessed the health-related risk attitude using the German version
of the 30-item Domain-Specific Risk-Taking (DOSPERT) scale
for adults (Blais and Weber, 2006). The DOSPERT scale contains
30 items in five distinct domains of risk taking (six items per
domain): ethical, financial, health/safety, recreational, and social.
The six items for health/safety were adapted to our questionnaire
in order to obtain the domain specific score. On a seven-point
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Likert scale (1 = very unlikely, 2 = unlikely, 3 = somewhat
unlikely, 4 = unsure, 5 = somewhat likely, 6 = likely, 7 = very
likely) the following items for the health/safety domain had to
be rated: how likely is it for you (i) drinking five or more
glasses of alcohol at one evening, (ii) engaging in unprotected
sex, (iii) driving a car without wearing a seat belt, (iv) riding a
motorcycle without a helmet, (v) sunbathing without sunscreen,
and (vi) walking home alone at night in an unsafe area of
town. For each student, the average rating to these items was
calculated. This score was used to classify the participants into
groups of higher or lower health-related risk attitude and enabled
us to calculate separate PN prevalence estimates for these two
subgroups. Finally, the third part of the questionnaire contained
four items concerning the participant’s characteristics: semester
(continuous), field of study (nominal), age (continuous), and
gender (male/female). The complete questionnaire is provided in
the Supplementary Material to this article.
Statistics
Descriptive data are presented as mean ± SD values for
continuous scaled variables and as numbers and percentages for
non-continuous scaled variables using SPSS software, version 22.
Prevalence estimates (pˆis) for PN are presented as percentages
with 95% confidence intervals (CI) and standard error (SE)
using Matlab version R2015a. Moreover, R software version 3.2.3
was used to perform large-sample z-tests for comparing the
prevalence estimates of PN between two groups (for example
between participants with lower and higher health-related risk
attitude). The central hypotheses of the study regarding the
influence of caffeine tablets and health-related risk attitude on PN
prevalence estimate were directed hypotheses and analyzed one-
tailed (right-tailed, α = 0.05). Non-directed variables (gender, age,
and semester) were analyzed two-tailed (α = 0.05). Therefore, the
continuous variables ‘age’ and ‘health related risk attitude’ were
dichotomized by median and in a second analysis the variable
‘semester’ manually by visual splitting.
RESULTS
A total number of 2,489 questionnaires were distributed among
students from the University of Graz and 2,464 (99%) were
returned. One hundred and eighty students stated that they had
already participated in the survey in a previous class/lecture and
hence these students were excluded from data analysis resulting
in a total number of 2,284 (91.8%) questionnaires for the analysis.
Mean age was 22.4 years (SD = 5.2 years), mean semester was
3.7 (SD = 2.5), 1,343 (59.1%) participants were female, and 1,138
(49.8%) obtained the questionnaire version that included caffeine
tablets in the example of PN. The 16 different fields of study
stated by the respondents were summarized into five groups
taking the local faculty affiliation of the different fields as well as
previous classification schemes (Dietz et al., 2013a) into account.
The mean health-related risk attitude assessed by the DOSPERT
scale was 22.3 (SD = 5.9). The respondent’s characteristics are
presented in Table 1.
The overall PN prevalence estimate for all students was
11.9% (Table 2). One-tailed large-sample z-tests revealed that
PN estimate for students with higher health-related risk attitude
was significantly higher (15.6%) compared to the group of
students with a lower (8.5%) health-related risk attitude (z = 2.65,
p = 0.004). Furthermore, when caffeine tablets were included
into the example of PN, the prevalence estimate of PN was
significantly higher (14.9%) compared to the version without
caffeine tablets (9.0%, z = 2.20, p = 0.014). Two-tailed large-
sample z-tests revealed that prevalence estimates were not
significantly different between female (10.2%) and male (14.9%)
participants (z = 1.70, p = 0.088), participants aged younger
than or equal to 21 years (12.3%) and older (11.7%) participants
(z = 0.22, p = 0.826) as well as between students studying in
the first (12.5%) or higher than first (11.5%) year (z = 0.37,
p = 0.712). Figure 1 presents the prevalence estimates together
with their 95% confidence intervals for the five different fields
of study indicating that the prevalence estimate is the lowest
in technical studies and informatics (5.4%) and the highest in
medicine, pharmacy, and psychology (14.9%). The prevalence
estimates for the remaining three groups were 11.5%, 11.5%, and
12.5%, respectively.
DISCUSSION
The present study addressed two questions. First, whether the PN
prevalence estimate increases when caffeine tablets are included
in the definition of PN. Second, whether the PN prevalence
estimate increases with increasing health-related risk attitude.
Therefore, a randomized-response survey was conducted among
university students at the University of Graz. Regarding the first
question, the present results support the assumption (Maier et al.,
2013; Liakoni et al., 2015; Maier and Schaub, 2015; Schleim and
TABLE 1 | Characteristics of the respondents.
Variable Value
Gender, no (%)
Female 1,343 (59.1)
Male 928 (40.9)
Age, range, years (mean ± SD) 16–85 (22.4 ± 5.2)
Semester, range (mean ± SD) 1–22 (3.7 ± 2.5)
Field of study#, no (%)
Technical studies and informatics 216 (9.8)
Natural sciences 431 (19.5)
Humanities, social sciences, languages and sport 597 (27.0)
Economy, law and USW 484 (21.9)
Medicine, pharmacy and psychology 486 (22.0)
Health-related risk attitude, range (mean ± SD) 6–42 (22.3 ± 5.9)
Questionnaire version, no (%)
With caffeine tablets 1,138 (49.8)
Without caffeine tablets 1,146 (50.2)
USW, Umweltsystemwissenschaften (environmental systems sciences). #The items
for the variable field of study were grouped on the basis of two previous studies and
modified according to the local affiliation of the different fields to the faculties.
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TABLE 2 | Estimated 12-month prevalence for pharmacological neuroenhancement.
Variable ‘Yes’ ‘No’ a pˆis(%) SE (pˆis) 95% CI
All students (n = 2,275)∗ 553 1,722 0.243 11.9 1.3 9.3–14.5
Gender
Female 310 1,029 0.232 10.2 1.7 6.8–13.6
Male 243 680 0.263 14.9 2.2 10.7–19.2
Age#
≤21 years 329 1,012 0.245 12.3 1.8 8.8–15.7
>21 years 222 698 0.241 11.7 2.1 7.5–15.8
Semester
1st or 2nd (first year) 295 899 0.247 12.5 1.9 8.9–16.2
>2nd 249 787 0.24 11.5 2.0 7.6–15.4
Health-related risk attitude#
≤22 256 908 0.22 8.5 1.8 4.9–12.0
>22 296 810 0.268 15.6 2.0 11.7–19.5
Questionnaire version
With caffeine tablets 298 835 0.263 14.9 2.0 11.1–18.7
Without caffeine tablets 255 887 0.223 9.0 1.8 5.4–12.6
∗Of the 2,284 students that filled in the questionnaire, nine students provided invalid results on the RRT question resulting in a total number of 2,275 valid responses. In
detail, three students made no cross and six students made two crosses by answering the RRT question but only one cross (‘yes’ OR ‘no’) is allowed. #Dichotomized by
median.
FIGURE 1 | Estimated 12-month prevalence and 95% confidence intervals for pharmacological neuroenhancement separated for field of study. USW,
Umweltsystemwissenschaften (environmental systems sciences).
Quednow, 2017) that the questionnaire version including caffeine
tablets in the PN definition increased the PN prevalence estimate
(14.9% without vs. 9.0% with caffeine tablets). This difference of
about 6% is consistent with the last-year prevalence for the use of
caffeine tablets for cognitive-enhancing purposes, which was also
reported to be about 6% (Franke et al., 2015). The results also
demonstrate the relevance of caffeine tablets from a public health
point of view, since the consumption of high dosages of caffeine
is discussed to be associated with comparable adverse health
effects as described for prescription and illicit psychoactive drugs
(Jackson et al., 2013; Temple et al., 2017). In addition, according
to several studies, high concentrations of caffeine (of 80 mg/L)
are considered lethal (Banerjee et al., 2014; Silva et al., 2014).
However, from a methodological point of view we have to stress
that participants who responded to version 2 of the questionnaire
(the version without caffeine tablets) may still have considered
caffeine tablets as PN. Consequently, we cannot directly assess
the prevalence of caffeine tablets but only calculate the difference
of prevalence estimation of PN between the two questionnaire
versions (with and without caffeine tablets).
Regarding the health-related risk attitude, the present results
provide evidence that the PN prevalence is higher in participants
with a higher health-related risk attitude (15.6%) compared to
participants with a lower health-related risk attitude (8.5%).
Consequently, our study supports the results of a previous study
performed among university students in Switzerland (Maier
et al., 2015). In their study, risk-taking-related personality
traits/attitudes such as novelty seeking, self-reported impulsivity
as well as antisocial personality were increased in users of
PN compared to controls. Likewise, previous studies reported
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comparable associations between risk attitude and the use of
other substances such as alcohol, tobacco, illicit drugs, and
doping substances (Khan et al., 2012; Noble et al., 2015; Nicholls
et al., 2017). This association might be of particular interest for
the student population, since the Centers for Disease Control
and Prevention of the United States and others have shown
that students engage in various health risk behaviors and ignore
preventive safety habits, which may have long-term implications
for their health (Centers for Disease Control and Prevention,
1997; Steptoe and Wardle, 2001; Steptoe et al., 2002; Von
Ah et al., 2004; Kann et al., 2013). Therefore, we conclude
that prevention and education programs addressing PN in the
collective of students likely fail if they only inform about potential
side effects of its use (approach of deterrence). In fact, such
programs have to further share knowledge about the limited
efficacy of PN in healthy individuals (Repantis et al., 2010; Ullrich
et al., 2015) and that using these substances is not associated
with better school marks (Franke et al., 2011a) nor with better
academic performance (McCabe et al., 2005). In addition,
students have to be informed about potential alternatives of PN
which are discussed to have cognitive-enhancing effects, such
as sports and exercise (Tomporowski, 2003; Lambourne and
Tomporowski, 2010; Dietz, 2013), nutrition (Chung et al., 2012),
sleep (Diekelmann and Born, 2010), or meditation (Lutz et al.,
2008; Sedlmeier et al., 2012).
The overall 12-month PN prevalence estimate of 11.9% for the
collective of university students in Graz, Austria is quite in the
middle of the heterogeneous prevalences reported for university
students from other countries in Europe (e.g., prevalence of
2% since the start of their university studies for Dutch (Schelle
et al., 2015) vs. 12-month prevalence of 20% for German (Dietz
et al., 2013a) university students. As stated above, the differences
across studies may be attributed to various methodological
factors. Additionally, the Dutch study did not include caffeine
tablets whereas the German study did. Since the present overall
prevalence estimate is a mix of both versions (with caffeine tablets
and without) it is quite plausible that this PN prevalence estimate
is quite in the middle of the Dutch and the German prevalence.
Finally, although the present study was the first large survey
assessing the prevalence of PN in Austrian University students
using RRT, the present results are not representative for Austria
because the survey was restricted to the University of Graz.
Nonetheless, we were able to demonstrate that the used study
design and survey techniques are highly appropriate to detect
cross-sectional associations between potential predictor variables
and PN.
The variables gender and semester did not significantly
influence PN prevalence estimates. For gender, our results
support the outcomes of other studies indicating that there is no
difference in the PN usage between female and male students
(Teter et al., 2006; Franke et al., 2011a; Mache et al., 2012).
Yet some studies reported gender differences, with males having
a higher risk for PN compared to females (DeSantis et al.,
2008; Arria et al., 2011). In a recent meta-analysis by Benson
et al. (2015), of 19 studies on gender differences in misuse
of stimulant medication among students, 13 studies reported
a higher prevalence for males compared to females, whereas
six studies observed no difference. This heterogeneous result
pattern may reflect differences in methodology, for example, by
using cross-sectional and longitudinal study designs, different
survey techniques as well as assessing prevalences for different
time periods such as lifetime versus last-year prevalence (Benson
et al., 2015). In contrast to the present study, a survey among
university students in Germany reported that students of the
first semester were of higher risk for PN compared to higher
semester students. In the present survey, only 105 participants
were first semester students. Therefore, we could not calculate
a reliable PN prevalence estimate for the first semester students
(Ulrich et al., 2012). To examine the influence of time spent at the
university on the prevalence of PN, future studies should collect
longitudinal data, which may enable researchers to assess changes
in PN consumption over time.
One limitation of the present study might be that we
used a self-designed question to assess the overall prevalence
of PN. This has been done for the following reason. It is
known from previous studies (e.g., doping in athletes) that
non-professional people are not aware about which substances
are illicit or need to be prescribed by a doctor. Therefore, we
provided a simple explanation by what we mean with “for
the purpose of enhancing your cognitive performance during
studying, have you used substances which are only available in
a pharmacy, can be prescribed by a doctor or can be bought
on the black marked during the last 12 month (examples)”
(Dietz et al., 2013a,b). One objection against this definition
might be that it excludes substances that can only be bought
in a pharmacy (e.g., high dosages of vitamins). Therefore, we
provided concrete examples of substances in order to increase
the comprehension of our question. It is likely that prevalence
estimates are influenced by how such questions are posed.
For example, the expression “prescription drugs for cognitive-
enhancement” seems ambivalent for readers and hence may
produce prevalence estimates that are too small compared to
the true prevalence. Another limitation of the study might
be that we were not able to identify specific substances for
PN by using the present RRT design to investigate an overall
prevalence estimate of PN. This gap should be closed by future
RRT studies that are tailored to address specific substance
prevalences.
Unrelated question model was used in the present study
to assess the PN prevalence estimate. UQM is one technique
among several RRTs [e.g., the forced response method, the item
count technique, the crosswise method, the cheater detection
model (CDM)]. In their meta-analysis of 38 randomized
response validation studies, Lensvelt-Mulders et al. (2005a)
have concluded that although RRT results are more valid
compared to results of conventional survey techniques,
there is still room for improvement (Lensvelt-Mulders et al.,
2005a). Using the UQM participants get randomly assigned to
answer one of two questions, the sensitive or a neutral one.
However, a participant that has been assigned to answer the
sensitive answer may avoid this question and respond to the
neutral question instead. As shown by Ulrich et al. (2018,
Supplementary Material, Section 4.3), this non-compliance
does not meaningfully distort the estimate obtained
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under the standard UQM assumptions. Moreover, a previous
study has shown that UQM and CDM, a model taking potential
cheating of participants into account, delivered comparable
prevalence estimates for a sensitive item (Schröter et al., 2016).
CONCLUSION
This study revealed that the PN prevalence estimate increases
when caffeine tablets are included in the definition of PN.
Therefore, future studies investigating the prevalence of, and
predictors for, PN should be performed and interpreted with
respect to potential framing effects. This study further revealed
that the PN prevalence estimate is increased in students with a
higher health-related risk attitude compared to students with a
lower one. Therefore, future education and prevention programs
addressing PN in the collective of students should not only
inform about potential side effects of its use but also address the
limited effects on cognition and potential alternatives of PN.
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